Company press releases
| Tid | Selskap | Tittel | Sektor | Kategori |
|---|---|---|---|---|
| 02 Nov 2023 08:00 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma: Presentation of third quarter 2023 results, November 9 | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 25 Oct 2023 13:23 CEST |
LYTIX BIOPHARMA AS | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 23 Oct 2023 08:00 CEST |
LYTIX BIOPHARMA AS | Encouraging preliminary data from Lytix Biopharma’s ATLAS-IT-05 study presented at ESMO 2023 | 20103010 Biotechnology | Innsideinformasjon |
| 20 Oct 2023 09:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma to host webcast after release of preliminary data from ATLAS-IT-05 | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 17 Oct 2023 08:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma granted up to NOK14.3m (US$1.3m) of public non-dilutive funding from ’SkatteFUNN’ | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 16 Oct 2023 08:51 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma’s abstract with preliminary interim Phase II data from the ATLAS-IT-05 study is published | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 09 Oct 2023 15:00 CEST |
LYTIX BIOPHARMA AS | Neoadjuvant study with LTX-315 in early-stage melanoma patients to be presented at the 15th Nordic melanoma meeting | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 31 Aug 2023 08:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma presents first half and second quarter 2023 results | 20103010 Biotechnology | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 28 Aug 2023 13:48 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma announces completion of patient recruitment in the ATLAS-IT-05 trial | 20103010 Biotechnology | Utsteders meldeplikt ved handel i egne aksjer |
| 24 Aug 2023 08:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma: Presentation of second quarter 2023 results, August 31 | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 11 Aug 2023 08:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma’s licensing partner Verrica Pharmaceuticals Inc. reports interim Phase II data with LTX-315 | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 03 Aug 2023 14:37 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma announces that Verrica Pharmaceuticals Inc. will present clinical results from their ongoing Phase II clinical study with LTX-315 (VP-315) at the 2023 American Academy of Dermatology Association’s Innovation Academy meeting | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 20 Jul 2023 08:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma announces presentation of interim data from ATLAS-IT-05 study at ESMO 2023 | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 21 Jun 2023 22:49 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma AS: GRANT OF SHARE OPTIONS | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 25 May 2023 08:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma to present at ABG Sundal Collier Life Science Summit and Redeye Growth Day in Stockholm | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 11 May 2023 08:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma presents first quarter 2023 results | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 04 May 2023 08:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma: Presentation of first quarter 2023 results, Thursday 11 May | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 03 May 2023 07:55 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma to present at the ‘Frontiers in Cancer Immunotherapy 2023’, invited by New York Academy of Sciences | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 19 Apr 2023 08:01 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma appoints new Chairman of the Board | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 18 Apr 2023 16:50 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma AS: GRANT OF SHARE OPTIONS | 20103010 Biotechnology | Meldepliktig handel for primærinnsidere |
| 18 Apr 2023 16:46 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma – Minutes of Ordinary General Meeting | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 11 Apr 2023 10:17 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma AS: Notice of Annual General Meeting on 18 April 2023 | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 30 Mar 2023 08:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma: Annual Report for 2022 | 20103010 Biotechnology | Årsrapporter og revisjonsberetninger |
| 16 Feb 2023 08:00 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma presents fourth quarter and second half 2022 results | 20103010 Biotechnology | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 09 Feb 2023 08:00 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma: Invitation to presentation of fourth quarter and second half 2022 results, Thursday 16 February | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 15 Dec 2022 15:08 CET |
LYTIX BIOPHARMA AS | Finansiell kalender | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 15 Dec 2022 15:08 CET |
LYTIX BIOPHARMA AS | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 14 Dec 2022 19:15 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma AS: GRANT OF SHARE OPTIONS | 20103010 Biotechnology | Meldepliktig handel for primærinnsidere |
| 17 Nov 2022 08:00 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma third quarter 2022 results | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 14 Nov 2022 08:00 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma announces expansion of the ATLAS-IT-05 study to Europe | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 10 Nov 2022 14:00 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma presents compelling data in collaboration with research groups at National Cancer Institute and Weill Cornell Medicine, USA. | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 10 Nov 2022 08:00 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma: Invitation to presentation of third quarter 2022 results, Thursday 17 November | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 01 Nov 2022 15:25 CET |
LYTIX BIOPHARMA AS | Invitation to Capital Markets Day in Oslo, November 22, 2022 | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 20 Oct 2022 13:54 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma to host Capital Markets Day - November 22, 2022 | 20103010 Biotechnology | Non-regulatory press releases |
| 05 Oct 2022 14:52 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma announces that an abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting | 20103010 Biotechnology | Non-regulatory press releases |
| 29 Sep 2022 11:23 CEST |
LYTIX BIOPHARMA AS | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 07 Sep 2022 08:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma announces approval to expand the ATLAS-IT-05 study to Europe | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 05 Sep 2022 08:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma appoints Stephen Worsley as Chief Business Officer | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 01 Sep 2022 18:41 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma: Mandatory notification of trade | 20103010 Biotechnology | Meldepliktig handel for primærinnsidere |
| 27 Aug 2022 12:48 CEST |
LYTIX BIOPHARMA AS | Mandatory notification of trade | 20103010 Biotechnology | Meldepliktig handel for primærinnsidere |
| 26 Aug 2022 15:06 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma: Mandatory notification of trade | 20103010 Biotechnology | Meldepliktig handel for primærinnsidere |
| 25 Aug 2022 07:59 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma: Second quarter and first half of 2022 results | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
| 18 Aug 2022 09:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma: Invitation to presentation of first half and second quarter 2022 results, Thursday August 25th, 2022 | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 05 Jun 2022 15:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma AS announces that LTX-315 in combination with Adoptive Cell Therapy has been shown to generate tumor-specific T cells and stabilize the disease in patients with progressive metastatic soft tissue sarcoma (STS) | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 27 May 2022 08:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma AS announces that an abstract on LTX-315 in combination with Adoptive Cell Therapy is selected for a poster presentation at ASCO 2022 | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 19 May 2022 16:41 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma – Invitation to Capital Markets Day in Oslo, June 1, 2022 | 20103010 Biotechnology | Non-regulatory press releases |
| 12 May 2022 08:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma presents first quarter 2022 results | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
| 05 May 2022 09:56 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma: Presentation of first quarter 2022 results, Thursday 12 May | 20103010 Biotechnology | Non-regulatory press releases |
| 03 May 2022 13:07 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma to host Capital Markets Day, save the date - June 1, 2022 | 20103010 Biotechnology | Non-regulatory press releases |
| 28 Apr 2022 11:54 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma to present at the American Society of Clinical Oncology (ASCO) Annual Meeting | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |